Cart
sales@molnova.com
R162
CAS No. 64302-87-0
R162( R162 | R 162 | R-162 )
Catalog No. M17560 CAS No. 64302-87-0
R162 is an effective glutamate dehydrogenase 1 (GDH1) inhibitor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 42 | In Stock |
|
| 5MG | 38 | In Stock |
|
| 10MG | 69 | In Stock |
|
| 25MG | 154 | In Stock |
|
| 50MG | 253 | In Stock |
|
| 100MG | 420 | In Stock |
|
| 200MG | 606 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameR162
-
NoteResearch use only, not for human use.
-
Brief DescriptionR162 is an effective glutamate dehydrogenase 1 (GDH1) inhibitor.
-
DescriptionR162 is an inhibitor of GDH activity and represses glioma cell growth.
-
In Vitro——
-
In Vivo——
-
SynonymsR162 | R 162 | R-162
-
PathwayAngiogenesis
-
TargetEGFR
-
Recptorglutamate dehydrogenase 1 (GDH1)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number64302-87-0
-
Formula Weight264.28
-
Molecular FormulaC17H12O3
-
Purity>98% (HPLC)
-
SolubilityDMSO : ≥ 100 mg/mL; 378.39 mM
-
SMILESO=C(C1=C2C=CC=C1)C3=CC=C(CC=C)C(O)=C3C2=O
-
Chemical Name2-Allyl-1-hydroxy-anthraquinone
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Jin L, et al. Glutamate dehydrogenase 1 signals through antioxidant glutathione peroxidase 1 to regulate redox homeostasis and tumor growth. Cancer Cell. 2015 Feb 9;27(2):257-70.
molnova catalog
related products
-
Lapatinib
A reversible, selective dual tyrosine kinase inhibitor of both EGFR and ErbB2 with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.
-
ICA-105574
ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
SKLB 1028
SKLB 1028 (Ruserontinib) is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. SKLB 1028 shows excellent activity in FLT3-driven AML models and considerable potency in CML models containing Abl mutants.
